Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2019029656) PYRIDAZINONE COMPOUND, METHOD FOR PREPARATION THEREOF, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF
Latest bibliographic data on file with the International BureauSubmit observation

Pub. No.: WO/2019/029656 International Application No.: PCT/CN2018/099806
Publication Date: 14.02.2019 International Filing Date: 10.08.2018
IPC:
C07D 401/04 (2006.01) ,C07D 403/12 (2006.01) ,C07D 401/12 (2006.01) ,A61K 31/5025 (2006.01) ,A61P 31/20 (2006.01)
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
401
Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
02
containing two hetero rings
04
directly linked by a ring-member-to-ring- member bond
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
403
Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/167
02
containing two hetero rings
12
linked by a chain containing hetero atoms as chain links
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
401
Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
02
containing two hetero rings
12
linked by a chain containing hetero atoms as chain links
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
495
having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
50
Pyridazines; Hydrogenated pyridazines
5025
ortho- or peri-condensed with heterocyclic ring systems
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
31
Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
12
Antivirals
20
for DNA viruses
Applicants:
中国科学院上海药物研究所 SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES [CN/CN]; 中国上海市 浦东张江祖冲之路555号 555 Zu Chong Zhi Road Zhang Jiang, Pudong Shanghai 201203, CN
Inventors:
胡有洪 HU, Youhong; CN
左建平 ZUO, Jianping; CN
陆栋 LU, Dong; CN
杨莉 YANG, Li; CN
曾丽敏 ZENG, Limin; CN
刘菲菲 LIU, Feifei; CN
张韫 吉吉 ZHANG, Yunzhe; CN
陈五红 CHEN, Wuhong; CN
童贤崑 TONG, Xiankun; CN
Agent:
北京坦路来专利代理有限公司 BEIJING TANLULAI PATENT AGENT LTD; 中国北京市 西城区新兴东巷15号10号楼3层312室 Suite 312, Floor 3, Building No. 10 Xinxingdongxiang No. 15, Xicheng District Beijing 100044, CN
Priority Data:
201710681892.X10.08.2017CN
Title (EN) PYRIDAZINONE COMPOUND, METHOD FOR PREPARATION THEREOF, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF
(FR) COMPOSÉ DE PYRIDAZINONE, PROCÉDÉ DE PRÉPARATION DE CELUI-CI, COMPOSITION PHARMACEUTIQUE ET UTILISATION CORRESPONDANTES
(ZH) 酞嗪酮类化合物、其制备方法、药物组合物及用途
Abstract:
(EN) Provided are a pyridazinone compound, method for preparation thereof, pharmaceutical composition thereof, and use thereof; the structure of said pyridazinone compound is as represented by formula I; the compound of said formula I is targeted to a viral nucleocapsid; it is possible to inhibit the replication of a virus by means of interference of the viral nucleocapsid, the replication activity of the DNA of the Hepatitis B virus is inhibited, and liver targeting is relatively good; the invention can exist stably in the liver and be enriched, and is a new and effective type of anti-Hepatitis B virus inhibitor.
(FR) L'invention concerne un composé de pyridazinone et un procédé de préparation de celui-ci, ainsi qu'une composition pharmaceutique et une utilisation associées; la structure dudit composé de pyridazinone est telle que représentée par la formule I; le composé de formule I est ciblé sur une nucléocapside virale; il est possible d'inhiber la réplication d'un virus au moyen d'une interférence de la nucléocapside virale, l'activité de réplication de l'ADN du virus de l'hépatite B est inhibée, et le ciblage du foie est relativement bon; l'invention peut exister de façon stable dans le foie et peut être enrichie, et est considérée comme un nouveau type efficace d'inhibiteur du virus de l'hépatite B.
(ZH) 酞嗪酮类化合物、其制备方法、药物组合物及用途,所述酞嗪酮类化合物结构如式I所示,所述式I化合物靶向作用于病毒核壳体,可通过对病毒核壳体的干扰抑制病毒的复制,具有高效的抑制乙型肝炎病毒DNA复制的活性,且具有较好的肝脏靶向性,能在肝脏稳定存在并富集,是一类新型的、有效的抗乙型肝炎病毒抑制剂。
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: Chinese (ZH)
Filing Language: Chinese (ZH)